BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 17047044)

  • 21. Role of TGF-beta in cancer and the potential for therapy and prevention.
    Kaklamani VG; Pasche B
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):649-61. PubMed ID: 15270668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of Apc in the mouse prostate causes prostate carcinoma.
    Bruxvoort KJ; Charbonneau HM; Giambernardi TA; Goolsby JC; Qian CN; Zylstra CR; Robinson DR; Roy-Burman P; Shaw AK; Buckner-Berghuis BD; Sigler RE; Resau JH; Sullivan R; Bushman W; Williams BO
    Cancer Res; 2007 Mar; 67(6):2490-6. PubMed ID: 17363566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell autonomous requirement for Tgfbr2 in the disappearance of medial edge epithelium during palatal fusion.
    Xu X; Han J; Ito Y; Bringas P; Urata MM; Chai Y
    Dev Biol; 2006 Sep; 297(1):238-48. PubMed ID: 16780827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.
    Grady WM; Myeroff LL; Swinler SE; Rajput A; Thiagalingam S; Lutterbaugh JD; Neumann A; Brattain MG; Chang J; Kim SJ; Kinzler KW; Vogelstein B; Willson JK; Markowitz S
    Cancer Res; 1999 Jan; 59(2):320-4. PubMed ID: 9927040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer.
    Brunschwig EB; Wilson K; Mack D; Dawson D; Lawrence E; Willson JK; Lu S; Nosrati A; Rerko RM; Swinler S; Beard L; Lutterbaugh JD; Willis J; Platzer P; Markowitz S
    Cancer Res; 2003 Apr; 63(7):1568-75. PubMed ID: 12670906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
    Hempen PM; Zhang L; Bansal RK; Iacobuzio-Donahue CA; Murphy KM; Maitra A; Vogelstein B; Whitehead RH; Markowitz SD; Willson JK; Yeo CJ; Hruban RH; Kern SE
    Cancer Res; 2003 Mar; 63(5):994-9. PubMed ID: 12615714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tgf-beta signaling alterations and colon cancer.
    Bellam N; Pasche B
    Cancer Treat Res; 2010; 155():85-103. PubMed ID: 20517689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
    Grady WM; Rajput A; Myeroff L; Liu DF; Kwon K; Willis J; Markowitz S
    Cancer Res; 1998 Jul; 58(14):3101-4. PubMed ID: 9679977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
    Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice.
    Oe S; Lemmer ER; Conner EA; Factor VM; Levéen P; Larsson J; Karlsson S; Thorgeirsson SS
    Hepatology; 2004 Nov; 40(5):1098-105. PubMed ID: 15389868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
    Go C; Li P; Wang XJ
    Cancer Res; 1999 Jun; 59(12):2861-8. PubMed ID: 10383147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
    Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
    Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
    Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
    Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling.
    Samuel MS; Suzuki H; Buchert M; Putoczki TL; Tebbutt NC; Lundgren-May T; Christou A; Inglese M; Toyota M; Heath JK; Ward RL; Waring PM; Ernst M
    Gastroenterology; 2009 Sep; 137(3):902-13, 913.e1-11. PubMed ID: 19454286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditional deletion of the TGF-beta type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones.
    Baffi MO; Slattery E; Sohn P; Moses HL; Chytil A; Serra R
    Dev Biol; 2004 Dec; 276(1):124-42. PubMed ID: 15531369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
    Yang F; Strand DW; Rowley DR
    Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.
    Li P; Schulz S; Bombonati A; Palazzo JP; Hyslop TM; Xu Y; Baran AA; Siracusa LD; Pitari GM; Waldman SA
    Gastroenterology; 2007 Aug; 133(2):599-607. PubMed ID: 17681179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
    Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
    Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The capacity for growth stimulation by TGF beta 1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras.
    Huang F; Hsu S; Yan Z; Winawer S; Friedman E
    Oncogene; 1994 Dec; 9(12):3701-6. PubMed ID: 7970729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.